FAQ on Soligenix Inc.'s Phase 3 HyBryte Trial and Business Update

What is Soligenix Inc. currently focusing on?

Soligenix Inc. is a late-stage biopharmaceutical company focusing on developing and commercializing products to treat rare diseases with unmet medical needs, including its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma (CTCL).

What is the significance of the Phase 3 FLASH2 trial?

The Phase 3 FLASH2 trial is significant as it evaluates HyBryte(TM) for CTCL treatment, with a design similar to the successful FLASH trial but with an extended treatment period of 18 consecutive weeks before assessing the primary efficacy endpoint.

When are the topline results for the FLASH2 trial expected?

Topline results for the FLASH2 trial are anticipated in 2026.

How does the FLASH2 trial differ from the FLASH trial?

The FLASH2 trial differs from the FLASH trial by treating patients for 18 consecutive weeks before assessing the primary efficacy endpoint, unlike the FLASH trial which measured the endpoint after the first treatment cycle of six weeks.

What other development programs does Soligenix have?

Soligenix’s development programs include synthetic hypericin for psoriasis, dusquetide for inflammatory diseases, and vaccine programs targeting filoviruses and COVID-19, among others.

Where can I find more information about Soligenix Inc.?

More information about Soligenix Inc. can be found on their website at www.Soligenix.com or in their newsroom at https://ibn.fm/SNGX.

What is the probability of success for the FLASH2 trial?

Based on the results from the FLASH trial, the FLASH2 trial has a high probability of success.

Who is supporting Soligenix’s vaccine programs?

Soligenix’s vaccine programs are supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).